ArcheMedX To Present New Findings & Clinical Trial Innovations At The 2022 CNS Summit

Share Article

Analyses of 42,656 clinician learners across 69 CNS-related educational activities reveals 80% of clinicians are not adequately prepared to conduct CNS-related clinical trials

ArcheMedX releases new findings on “The State of CNS Clinician Readiness” at the 2022 CNS Summit

Data demonstrates more than 80% of clinicians are not adequately prepared to conduct a CNS-related clinical trial

ArcheMedX, the leading provider of clinician readiness solutions for the life sciences and healthcare industries, today announced the Company’s expanded participation at the CNS Summit taking place November 17th-20th in Boca Raton, Florida.

The Company will present highly anticipated new findings on “The State of CNS Clinician Readiness” at this year’s CNS Summit revealing the educational needs of clinicians treating patients and conducting clinical research across CNS-related conditions. ArcheMedX will also showcase how trial sponsors and CROs are deploying Ready, the Company’s innovative learning and predictive analytics platform to streamline study startup and optimize clinical trial delivery.

The 2022 edition of “The State of CNS Clinician Readiness” findings examine how many of the challenges in conducting more complex CNS-related studies are rooted in underlying process inefficiencies, performance challenges, and training gaps. The report reveals critical insights from analyses of learner data generated by 42,626 clinicians researching and treating neurological disorders such as Alzheimer's, Migraine, MDD, MS, and Bipolar/Schizophrenia.

The data, analyzed across professions and clinical areas, demonstrate that more than 80% of clinicians are not adequately prepared to formulate a differential diagnosis, develop individualized treatment plans, or navigate the complexity of CNS care teams to provide appropriate treatment.

These variations in clinician mastery and deficiencies in readiness may delay patient enrollment, increase clinical trial costs, and worsen healthcare outcomes in clinical trials conducted across neurological disorders. Trial risks such as these can be reduced by delivering more tailored and effective study training that improves readiness across key research and treatment objectives.

Fortunately, the same 42,626 clinician learners demonstrated significant increases in mastery after completing more tailored and effective on-demand training powered by the Ready platform. The ArcheMedX team will present detailed findings at the CNS Summit during Friday’s Poster Session (poster #6) and Saturday’s Innovation Showcase at 2:30pm.

Visit https://www.info.archemedx.com/cnssummit2022 to connect with the ArcheMedX team at the CNS Summit.

Download an advanced copy of “The State of CNS Clinician Readiness” report today and learn more about the Ready platform at https://www.archemedx.com/ready/.

--
About ArcheMedX
ArcheMedX predicts and improves team and clinician performance, delivering better clinical trials and faster clinical adoption for 21 of the top 25 pharmaceutical firms, emerging biotechs, and nationally recognized healthcare organizations. To learn more about the industry’s leading behavioral learning and predictive analytics platform, Ready, and its impact across clinical operations, medical affairs, and patient care, visit https://www.archemedx.com/ or follow ArcheMedX on LinkedIn.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Emily Farmer